Manufacturer of Controlled Substances; Notice of Registration, 10070 [2011-3924]
Download as PDF
<![CDATA[
10070
Federal Register / Vol. 76, No. 36 / Wednesday, February 23, 2011 / Notices
Johnson Matthey Inc. to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Johnson Matthey Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: February 15, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: February 16, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–3924 Filed 2–22–11; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Parole Commission
[FR Doc. 2011–3925 Filed 2–22–11; 8:45 am]
[5 U.S.C. Section 552b]
BILLING CODE 4410–09–P
Meetings; Sunshine Act; Public
Announcement Pursuant to the
Government in the Sunshine Act
Public Law 94–409
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
By Notice dated October 8, 2010, and
published in the Federal Register on
October 20, 2010, 75 FR 64745, Halo
Pharmaceutical Inc., 30 North Jefferson
Road, Whippany, New Jersey 07981,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Schedule
mstockstill on DSKH9S0YB1PROD with NOTICES
Dihydromorphine (9145) ...............
Hydromorphone (9150) ................
I
II
Dihydromorphine is an intermediate
in the manufacture of Hydromorphone
and is not for commercial distribution.
The company plans to manufacture
Hydromorphone HCL for sale to other
manufacturers and for the manufacture
of other controlled substance dosage
units for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Halo
Pharmaceutical Inc. to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Halo Pharmaceutical Inc. to
ensure that the company’s registration is
consistent with the public interest. The
VerDate Mar<15>2010
18:50 Feb 22, 2011
Jkt 223001
Dated: February 11, 2011.
Isaac Fulwood,
Chairman, U.S. Parole Commission.
[FR Doc. 2011–3891 Filed 2–22–11; 8:45 am]
Department of
Justice, United States Parole
Commission.
DATE AND TIME: 10 a.m., Thursday,
February 17, 2011.
PLACE: U.S. Parole Commission, 5550
Friendship Boulevard, 4th Floor, Chevy
Chase, Maryland 20815.
STATUS: Closed.
MATTERS CONSIDERED: The following
matter will be considered during the
closed meeting: Discussion of an
original jurisdiction case pursuant to 28
CFR 2.17.
AGENCY CONTACT: Patricia W. Moore,
Staff Assistant to the Chairman, United
States Parole Commission, (301) 492–
5933.
AGENCY HOLDING MEETING:
Manufacturer of Controlled
Substances; Notice of Registration
Drug
Parole Commission, 5550 Friendship
Boulevard, 4th Floor, Chevy Chase,
Maryland 20815. The purpose of the
meeting was to decide four petitions for
reconsideration pursuant to 28 CFR
Section 2.27 and one pursuant to 28
CFR Section 2.17. Four Commissioners
were present, constituting a quorum
when the vote to close the meeting was
submitted.
Public announcement further
describing the subject matter of the
meeting and certifications of General
Counsel that this meeting may be closed
by vote of the Commissioners present
were submitted to the Commissioners
prior to the conduct of any other
business. Upon motion duly made,
seconded, and carried, the following
Commissioners voted that the meeting
be closed: Isaac Fulwood, Cranston J.
Mitchell, Patricia Cushwa and J. Patricia
Wilson Smoot.
In witness whereof, I make this official
record of the vote taken to close this
meeting and authorize this record to be
made available to the public.
Dated: February 15, 2011,
Rockne Chickinell,
General Counsel, U.S. Parole Commission.
[FR Doc. 2011–3902 Filed 2–22–11; 8:45 am]
BILLING CODE 4410–31–M
DEPARTMENT OF JUSTICE
United States Parole Commission
Record of Vote of Meeting Closure
(Pub. L. 94–409) (5 U.S.C. Sec. 552b)
I, Isaac Fulwood, of the United States
Parole Commission, was present at a
meeting of said Commission, which
started at approximately 11:30 a.m., on
Thursday, February 10, 2011, at the U.S.
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
BILLING CODE 4410–01–M
DEPARTMENT OF LABOR
Office of Workers’ Compensation
Programs
Division of Coal Mine Workers’
Compensation; Proposed Extension of
Existing Collection; Comment Request
ACTION:
Notice.
The Department of Labor, as
part of its continuing effort to reduce
paperwork and respondent burden,
conducts a pre-clearance consultation
program to provide the general public
and Federal agencies with an
opportunity to comment on proposed
and/or continuing collections of
information in accordance with the
Paperwork Reduction Act of 1995
(PRA95) [44 U.S.C. 3506(c)(2)(A)]. This
program helps to ensure that requested
data can be provided in the desired
format, reporting burden (time and
financial resources) is minimized,
collection instruments are clearly
understood, and the impact of collection
requirements on respondents can be
properly assessed. Currently, the Office
of Workers’ Compensation Programs is
soliciting comments concerning its
proposal to extend OMB approval of the
information collection for the following
medical reports:
SUMMARY:
E:\FR\FM\23FEN1.SGM
23FEN1
]]>Agencies
[Federal Register Volume 76, Number 36 (Wednesday, February 23, 2011)]
[Notices]
[Page 10070]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-3924]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated October 8, 2010, and published in the Federal
Register on October 20, 2010, 75 FR 64745, Halo Pharmaceutical Inc., 30
North Jefferson Road, Whippany, New Jersey 07981, made application by
renewal to the Drug Enforcement Administration (DEA) to be registered
as a bulk manufacturer of the following basic classes of controlled
substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Dihydromorphine (9145)..................... I
Hydromorphone (9150)....................... II
------------------------------------------------------------------------
Dihydromorphine is an intermediate in the manufacture of
Hydromorphone and is not for commercial distribution. The company plans
to manufacture Hydromorphone HCL for sale to other manufacturers and
for the manufacture of other controlled substance dosage units for
distribution to its customers.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Halo Pharmaceutical Inc. to manufacture the listed basic classes of
controlled substances is consistent with the public interest at this
time. DEA has investigated Halo Pharmaceutical Inc. to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance
with 21 CFR 1301.33, the above named company is granted registration as
a bulk manufacturer of the basic classes of controlled substances
listed.
Dated: February 16, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-3924 Filed 2-22-11; 8:45 am]
BILLING CODE 4410-09-P
